BioSpace News Archive

Plus Therapeutics (NASDAQ:PSTV), is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets, including recurrent glioblastoma. PSTV will be presenting at the virtual Fall Investor Summit on November 16 th -18 th .

Danish drug formulation company ZERION announces the appointment of Dr. Wei Tian as Director of CMC development. He will join ZERION’s management team from November 2020.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN® will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Healthcare Conference on November 19 at 12 p.m. EST. The Company will also be participating in the virtual Piper Sandler 32nd Annual Healthcare Conference being held December 1-3. A live audio webcast of the

Lahey Hospital & Medical Center has acquired the XACT ACE™ Robotic System, for use in its leading Interventional Radiology service. ACE is the world’s first hands-free robotic technology combining advanced image-based procedure planning and navigation with robotic instrument insertion and steering capabilities enabling radiologists to deliver site-specific percutaneous solutions with accuracy, consistency, and efficiency

TYME revealed potential new oral therapy, TYME-19, in the fight against COVID-19 based on its cancer metabolism research program

Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses

Trefoil Therapeutics, which is developing first-in-class regenerative treatments for corneal diseases, announced today it has received the ‘People’s Choice’ award at the inaugural Eyecelerator virtual conference. The company’s lead product, an engineered fibroblast growth factor 1 (FGF-1, TTHX1114) administered by intracameral (behind the cornea) injection, recently entered a Phase 1/2 clinical trial for the treatment of endot

Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda ® , to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo ® ) in the treatment of cancer. Veyonda is a first-in-class sphingosine-1-phosphate inhibitor with h

Nov. 12, 2020 13:00 UTC Zoetis Receives European Commission Marketing Authorization for Librela ® (bedinvetmab) The first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs Librela works differently from other pain medications, combining one month of pain control and increased mobility, with a proven safety and efficacy profile Librela has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis